CoChat
Sign Up
Cited by 116

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease

Poirier, Judes·2003·Trends in Molecular Medicine
DOI 10.1016/s1471-4914(03)00007-8
Open this paper in CoChat — free account

Abstract

There is much evidence suggesting that there is a strong relationship between the deterioration of brain lipid homeostasis, vascular changes and the pathogenesis of Alzheimer's disease (AD). These associations include: (1). recognition that a key cholesterol transporter, apolipoprotein E type 4, acts a major genetic risk factor for both familial and sporadic AD; (2). epidemiological studies linking cardiovascular risk factors, such as hypertension and high plasma cholesterol, to dementia; (3). the discovery that small strokes can precipitate clinical dementia in cognitively normal elderly subjects; (4). the modulation of degradation of the amyloid precursor protein by cholesterol administration in cell culture and in animal models of beta-amyloid overproduction; and (5). the beneficial effect of cholesterol-lowering drugs, such as Probucol and statins, in combating common AD. The recent finding that there is a genetic association between the HMGR gene locus and sporadic AD further suggests that brain cholesterol metabolism is central to AD pathophysiology, and a potential therapeutic target for disease stabilization and primary disease prevention.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1471-4914(03)00007-8

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 44

  1. Tanzi, 2001, New frontiers in Alzheimer's disease genetics, Neuron, 32, 181, 10.1016/S0896-6273(01)00476-7 · DOI
  2. Poirier, 1993, Apolipoprotein E polymorphism and Alzheimer's disease, Lancet, 342, 697, 10.1016/0140-6736(93)91705-Q · DOI · Paper page
  3. Strittmatter, 1993, Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc. Natl. Acad. Sci. U. S. A., 90, 1977, 10.1073/pnas.90.5.1977 · DOI · Paper page
  4. Kalaria, 1999, Overlap between pathology of Alzheimer disease and vascular dementia, Alzheimer Dis. Assoc. Disord., 13, S115, 10.1097/00002093-199912003-00017 · DOI
  5. de Leon, 2001, Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET), Proc. Natl. Acad. Sci. U. S. A., 98, 10966, 10.1073/pnas.191044198 · DOI · Paper page
  6. Reiman, 2001, Declining brain activity in cognitively normal apolipoprotein E ϵ4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 98, 3334, 10.1073/pnas.061509598 · DOI · Paper page
  7. Luchsinger, 2002, Caloric intake and the risk of Alzheimer disease, Arch. Neurol., 59, 1258, 10.1001/archneur.59.8.1258 · DOI
  8. Peila, 2001, Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu–Asia aging study, Stroke, 32, 2882, 10.1161/hs1201.100392 · DOI
  9. Mulnard, 2000, Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's disease cooperative study, JAMA, 283, 1007, 10.1001/jama.283.8.1007 · DOI
  10. Distl, 2001, Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons, Acta Neuropathol. (Berl.), 101, 547, 10.1007/s004010000314 · DOI
  11. Mulder, 1998, Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4, Alzheimer Dis. Assoc. Disord., 12, 198, 10.1097/00002093-199809000-00012 · DOI
  12. Svennerholm, 1994, Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II), J. Neurochem., 62, 1039, 10.1046/j.1471-4159.1994.62031039.x · DOI
  13. Mason, 1992, Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol, Neurobiol. Aging, 13, 413, 10.1016/0197-4580(92)90116-F · DOI
  14. Giubilei, 1990, Serum lipoprotein pattern variations in dementia and ischemic stroke, Acta Neurol. Scand., 81, 84, 10.1111/j.1600-0404.1990.tb00936.x · DOI
  15. Jarvik, 1995, Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study, Neurology, 45, 1092, 10.1212/WNL.45.6.1092 · DOI
  16. Roher, 1999, Amyloid and lipids in the pathology of Alzheimer disease, Amyloid, 6, 136, 10.3109/13506129909007315 · DOI
  17. Kehoe, 1999, A full genome scan for late onset Alzheimer's disease, Hum. Mol. Genet., 8, 237, 10.1093/hmg/8.2.237 · DOI
  18. Yasojima, 2001, 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain, Neuroreport, 12, 2935, 10.1097/00001756-200109170-00036 · DOI
  19. Poirier, 1993, Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats, Neuroscience, 55, 81, 10.1016/0306-4522(93)90456-P · DOI
  20. Nathan, 1994, Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro, Science, 264, 850, 10.1126/science.8171342 · DOI · Paper page
  21. Poirier, 1995, Apolipoprotein E, synaptic plasticity and Alzheimer's disease, Ann. Med., 27, 663, 10.3109/07853899509019253 · DOI
  22. Beffert, 1996, Apolipoprotein E uptake is increased by β-amyloid peptides and reduced by blockade of the LDL receptor, Mol. Brain Res., 68, 181, 10.1016/S0169-328X(99)00073-X · DOI
  23. Sliskovic, 1991, Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents, Trends Pharmacol. Sci., 12, 194, 10.1016/0165-6147(91)90546-5 · DOI
  24. Sparks, 1994, Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol, Exp. Neurol., 126, 88, 10.1006/exnr.1994.1044 · DOI · Paper page
  25. Schmechel, 2002, High saturated fat diets are associated with a β deposition in primates, Neurobiol. Aging, 23, 323
  26. Refolo, 2000, Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model, Neurobiol. Dis., 7, 321, 10.1006/nbdi.2000.0304 · DOI · Paper page
  27. Shie, 2002, Diet-induced hypercholesterolemia enhances brain Aβ accumulation in transgenic mice, Neuroreport, 13, 455, 10.1097/00001756-200203250-00019 · DOI · Paper page
  28. Howland, 1998, Modulation of secreted β-amyloid precursor protein and amyloid β-peptide in brain by cholesterol, J. Biol. Chem., 273, 16576, 10.1074/jbc.273.26.16576 · DOI
  29. Beffert, 1996, Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease, Ann. New York Acad. Sci., 777, 166, 10.1111/j.1749-6632.1996.tb34415.x · DOI
  30. Beffert, 1999, Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures, Mol. Brain Res., 68, 181, 10.1016/S0169-328X(99)00073-X · DOI
  31. Puglielli, 2001, Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide, Nat. Cell Biol., 3, 905, 10.1038/ncb1001-905 · DOI · Paper page
  32. Bodovitz, 1996, Cholesterol modulates α-secretase cleavage of amyloid precursor protein, J. Biol. Chem., 271, 4436, 10.1074/jbc.271.8.4436 · DOI · Paper page
  33. Fassbender, 2001, Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo, Proc. Natl. Acad. Sci. U. S. A., 98, 5856, 10.1073/pnas.081620098 · DOI · Paper page
  34. Refolo, 2001, A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease, Neurobiol. Dis., 8, 890, 10.1006/nbdi.2001.0422 · DOI
  35. Aboushadi, 2000, Characterization of peroxisomal 3-hydroxy-3-methylglutaryl coenzyme A reductase in UT2 cells: sterol biosynthesis, phosphorylation, degradation, and statin inhibition, Biochemistry, 39, 237, 10.1021/bi9916325 · DOI
  36. Reynolds, 1984, HMG CoA reductase: a negatively regulated gene with unusual promoter and 5′ untranslated regions, Cell, 38, 275, 10.1016/0092-8674(84)90549-X · DOI
  37. Gardner, 1999, A highly conserved signal controls degradation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in eukaryotes, J. Biol. Chem., 274, 31671, 10.1074/jbc.274.44.31671 · DOI
  38. Jick, 2000, Statins and the risk of dementia, Lancet, 356, 1627, 10.1016/S0140-6736(00)03155-X · DOI
  39. Rockwood, 2002, Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people, Arch. Neurol., 59, 223, 10.1001/archneur.59.2.223 · DOI
  40. Wolozin, 2000, Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors, Arch. Neurol., 57, 1439, 10.1001/archneur.57.10.1439 · DOI
  41. Poirier, 2002, Apolipoprotein E: A novel therapeutic target for the treatment of Alzheimer's Disease, Adv. Behav. Biol., 1, 36
  42. Friedhoff, 2001, Treatment with controlled-release lovastatin decreases serum concentrations of human β-amyloid (Aβ) peptide, Int. J. Neuropsychopharmacol., 4, 127, 10.1017/S1461145701002310 · DOI
  43. Hardy, 1992, Alzheimer's disease: the amyloid cascade hypothesis, Science, 256, 184, 10.1126/science.1566067 · DOI · Paper page
  44. Poirier, 1994, Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease, Trends Neurosci., 17, 525, 10.1016/0166-2236(94)90156-2 · DOI

Cited by

Sorted by citations

Metadata

Authors
Poirier, J.
Venue
Trends in Molecular Medicine
Publisher
Elsevier BV
Published
2003-03
Volume
9
Issue
3
Pages
94-101
ISSN
1471-4914
DOI
10.1016/s1471-4914(03)00007-8
Cited by
116
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review